Results from a Phase 2 Trial of Senolytic Therapy Dasatinib and Quercetin for Osteoporosis
Senescent cells, which accumulate with age, can disrupt tissue structure and function in the body. The combination of dasatinib and quercetin has shown promise in clearing senescent cells in clinical trials. Initial results from a Mayo Clinic study in older women with osteoporosis were positive, demonstrating improvements in bone mineral density for those with a higher burden of senescent cells. While fisetin is also being studied as a senolytic treatment, more research is needed to determine its effectiveness. Intermittent senolytic treatment with dasatinib and quercetin has shown benefits for bone formation in postmenopausal women. Further studies are needed to understand the impact of senescent cell burden on the efficacy of senolytic therapies.
